TLDR
- GCTK drops ~30% to $2.38 as selling wipes out an early $5.7 spike
- Three USPTO patents land, yet GCTK breaks ~$3.4 and slides to $2.38
- GlucoTrack patents strengthen CBGM IP, but GCTK fades hard on the chart
- GCTK sinks 29.86% despite new CBGM patents for implantable glucose tech
- Volatility surges: GCTK reverses from $5.7 and stabilizes near $2.4
GCTK shares fell to $2.38, down 29.86%, after a sharp intraday reversal erased an early surge. Glucotrack, Inc. stock slides ~30% despite a trio of fresh USPTO patents for the implantable CBGM platform. Price spiked near $5.7, then broke below about $3.4, and later steadied around the $2.4 area.
GCT Semiconductor Holding, Inc., GCTS
GCTK patents secure key implantable CBGM elements
Glucotrack, Inc. stock slides ~30% despite a trio of fresh USPTO patents for the implantable CBGM platform. USPTO issued three patents for the continuous blood glucose monitoring platform, with issue dates in late 2025. The grants include US 12,453,494 on Oct. 28 and US 12,458,257 and US 12,458,258 on Nov. 4.
Glucotrack, Inc. stock slides ~30% despite a trio of fresh USPTO patents for the implantable CBGM platform. The filings cover sensor chemistry, an intravascular lead design, and low-power electronics that support long sensor life. They target reduced decay and lag, plus less surface blockage that can distort readings over time.
The portfolio can raise barriers for rivals, and it can support partnering talks as development continues. Glucotrack positions the patents as core protection for a multi-year implantable system that aims for commercialization. Patents do not guarantee revenue, and the company still must clear clinical and regulatory gates.
GCTK device concept targets multi-year monitoring
Glucotrack, Inc. stock slides 30% despite a trio of fresh USPTO patents for the implantable CBGM platform. The CBGM concept uses an implantable sensor with no wearable part, and it targets up to three years use. It measures glucose directly from blood, so it aims to reduce delays linked to interstitial measurements.
Most commercial continuous glucose monitors use skin-worn sensors that sample interstitial fluid and require frequent replacement. Glucotrack’s implantable approach seeks longer life and lower daily burden, yet it adds procedure and follow-up needs. Adoption may depend on clinical accuracy, safety signals, and how payers price the implantable model.
Glucotrack, Inc. stock slides ~30% despite a trio of fresh USPTO patents for the implantable CBGM platform. Glucotrack operates as a medical device developer, and it plans further testing as it builds a commercialization pathway. The stock action showed traders weighed dilution and execution risk, even as IP coverage strengthened.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
